# Primary Osteoarthritis Market

> Primary Osteoarthritis Market Research Report Information By Type (Knee, Hand, Neck, Hip, Wrist, Spinal, and Shoulder Osteoarthritis), Product Type, Drug Class (Combination Drug, LTA, ICS, SABA, LABA), Route of Administration, End User – Global Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.18%
- **2024:** $ 6.93 Billion
- **2025:** $ 7.5 Billion
- **2035:** $ 16.46 Billion
- **Key Players:** Pfizer (US), Johnson & Johnson (US), Bristol-Myers Squibb (US), Novartis (CH), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US)

**Report ID:** MRFR/Pharma/3937-HCR · **Pages:** 120 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/primary-osteoarthritis-market-5380

---

## Market Summary

## **Global Primary Osteoarthritis Market Overview**

Primary Osteoarthritis Market Size was valued at USD 5.63 Billion in 2023. The Global Primary Osteoarthritis industry is projected to grow from USD 6.93 Billion in 2024 to USD 12.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.42% during the forecast period (2024 - 2032).Arthritis refers to inflammation of the joint, accompanied by joint pain and stiffness. It may be acute or chronic. Obesity, infections, crystal deposition, joint injury, and old age are some of the common causes associated with arthritis. Osteoarthritis and rheumatoid arthritis are two common types of arthritis.

Osteoarthritis is a chronic disease, which affects joints, including ligament, cartilage, joint lining, and underlying bones. This disease results in joint pain and stiffness due to the breakdown of cartilage. It is also known as Degenerative Joint Disease (DJD). Primary osteoarthritis and secondary osteoarthritis are the two major forms of osteoarthritis. Primary osteoarthritis results from abnormal stress on weight-bearing joints. This is prevalent mostly in the aging population.

Physical therapy, occupational therapy, chronic pain class, and braces are some of the therapies associated with osteoarthritis. Moreover, osteoarthritis treatment includes surgical procedures such as lubrication injections, [cortisone shots](../../../reports/cortisone-shots-market-4847), and joint replacement. Rising incidences of surgeries, increasing technological advancements, increasing number of pipeline drugs, and rising awareness about health care are some of the key factors driving the growth of the osteoarthritis market. In addition, rising disposable income in developing countries is also fueling the growth of the osteoarthritis market.

However, stringent regulatory policies and less adoption of osteoarthritis treatment are restraining the growth of the osteoarthritis market. In addition, side effects associated with osteoarthritis medications are also impeding the growth of Primary Osteoarthritis Market.

**Intended Audience**

## **Primary Osteoarthritis Market Segment Insights**

The primary osteoarthritis market is segmented on the basis of type, diagnosis, treatment, and end-users.

### **Primary Osteoarthritis Type Insights**

On the basis of the type, the market is segmented into knee osteoarthritis, hand osteoarthritis, neck osteoarthritis, hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, shoulder osteoarthritis, and others

### **Primary Osteoarthritis Diagnosis Insights**

On the basis of the diagnosis, the Primary Osteoarthritis Market is segmented into imaging, joint fluid analysis, and others. The imaging segment is further classified into divided X-rays, Magnetic resonance imaging (MRI), and others.

### **Primary Osteoarthritis Treatment Insights**

On the basis of the treatment, the Primary Osteoarthritis Market is segmented into medication, therapies, surgery, and others. The medication segment can be classified into analgesics and non-steroidal anti-inflammatory drugs. The analgesics segment is further classified as acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory drugs can be further classified into aspirin, ibuprofen, naproxen sodium/ naproxen, and others.

### **Primary Osteoarthritis End-user Insights**

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

### **Primary Osteoarthritis Regional Insights  **    

The primary osteoarthritis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

Currently, North America dominates the osteoarthritis market, followed by Europe. This is due to the rising prevalence of osteoarthritis diseases and growing geriatric population in these regions. In addition, increasing access to health care insurance, especially in the U.S., is also influencing the growth of the Primary Osteoarthritis Market.

The European primary osteoarthritis market is expected to witness rapid growth owing to the high investment in various private and government-funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

Asia is expected to be the fastest growing market in the next five years. This is due to the rising healthcare infrastructure and increasing government initiatives for better health care facilities in this region. Moreover, a large patient population base is driving the growth of the Primary Osteoarthritis Market in this region.  

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

**Key Players**

The emergence of new and cost-effective medication options for the treatment of osteoarthritis could open up new opportunities for new players in the osteoarthritis market. In addition, emerging markets, such as India and China, could also open new opportunities for new players. Increasing number of strategic alliances between various companies, rising number of product innovations, and increase in the number of clinical trials for pain reliving biologic drugs, such as anti-NGFs, are among the recent market trends in the Primary Osteoarthritis Market.

Some of key the players in the primary osteoarthritis market are

## Market Drivers

### Rising Awareness and Education

There is a notable increase in awareness and education regarding osteoarthritis, which serves as a crucial driver for the Primary Osteoarthritis Market. Public health campaigns and educational initiatives have been instrumental in informing individuals about the symptoms, risk factors, and management strategies associated with osteoarthritis. This heightened awareness encourages early diagnosis and treatment, potentially leading to better patient outcomes. As more individuals recognize the importance of addressing osteoarthritis, the demand for healthcare services, including consultations and therapies, is likely to rise. Consequently, this trend may stimulate growth within the Primary Osteoarthritis Market.

### Advancements in Diagnostic Techniques

Advancements in diagnostic techniques are significantly influencing the Primary Osteoarthritis Market. Enhanced imaging technologies, such as MRI and ultrasound, allow for more accurate and earlier diagnosis of osteoarthritis. These innovations facilitate timely intervention, which is crucial for managing the condition effectively. As diagnostic capabilities improve, healthcare providers are better equipped to identify osteoarthritis in its early stages, leading to increased treatment uptake. This trend is likely to drive growth in the Primary Osteoarthritis Market, as patients seek out advanced diagnostic services and subsequent treatment options.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is emerging as a pivotal driver in the Primary Osteoarthritis Market. Tailoring treatment plans to individual patient profiles, including genetic and lifestyle factors, enhances the effectiveness of interventions. This approach not only improves patient outcomes but also fosters greater patient engagement in their treatment journey. As healthcare providers increasingly adopt personalized strategies, the demand for specialized therapies and monitoring tools is expected to rise. This trend may lead to a more dynamic and responsive Primary Osteoarthritis Market, catering to the unique needs of patients.

### Aging Population and Increased Prevalence

The aging population is a primary driver of the Primary Osteoarthritis Market. As individuals age, the likelihood of developing osteoarthritis increases significantly. Data indicates that approximately 27 million adults in the United States alone are affected by osteoarthritis, with the prevalence expected to rise as the population ages. This demographic shift suggests a growing need for effective management and treatment options within the Primary Osteoarthritis Market. Furthermore, the increasing life expectancy in various regions contributes to a higher incidence of osteoarthritis, thereby amplifying the demand for healthcare services and interventions tailored to this condition.

### Growth of Rehabilitation and Physical Therapy Services

The growth of rehabilitation and physical therapy services is a significant driver for the Primary Osteoarthritis Market. As healthcare systems recognize the importance of non-invasive treatment options, there is an increasing emphasis on rehabilitation programs designed to alleviate symptoms and improve mobility for osteoarthritis patients. Data suggests that physical therapy can lead to substantial improvements in function and pain management. Consequently, the demand for physical therapy services is likely to rise, further propelling the growth of the Primary Osteoarthritis Market as patients seek comprehensive care solutions.

## Future Outlook

The Primary Osteoarthritis Market is projected to grow at an 8.18% CAGR from 2025 to 2035, driven by increasing aging populations, rising obesity rates, and advancements in treatment options.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring Investment in regenerative medicine technologies for joint repair Expansion of personalized treatment plans using AI-driven analytics

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.

## Segment Insights

### By Type: Knee Osteoarthritis (Largest) vs. Hip Osteoarthritis (Fastest-Growing)

The Primary Osteoarthritis Market is primarily dominated by knee osteoarthritis, which accounts for a substantial share of the overall market. This segment has been consistently the largest due to the high prevalence of knee-related issues in the aging population and among those leading active lifestyles. Hand osteoarthritis and hip osteoarthritis also contribute significantly, with the latter witnessing notable growth due to rising instances of obesity and a greater emphasis on active living, further contributing to joint wear.

Knee Osteoarthritis (Dominant) vs. Hip Osteoarthritis (Emerging)

Knee osteoarthritis dominates the Primary Osteoarthritis Market, primarily due to its high incidence in older adults and those engaged in physical activities that impose stress on knee joints. The awareness around knee health and the availability of various treatment options solidify its market position. Conversely, hip osteoarthritis is emerging as a significant segment driven by increasing obesity rates and lifestyle changes leading to earlier joint degeneration. This segment benefits from advancements in treatment approaches and a growing focus on preventive care, positioning it as a key opportunity for growth in the coming years.

### By Diagnosis: Imaging (Largest) vs. Joint Fluid Analysis (Fastest-Growing)

In the Primary Osteoarthritis Market, the Diagnosis segment is predominantly represented by imaging techniques, which hold the largest share. These imaging techniques include X-rays, MRIs, and CT scans, and they are crucial in evaluating joint degeneration and osteophyte formation. Joint fluid analysis, while smaller in market share, is becoming increasingly relevant, providing essential information about the biochemical composition of joint fluids and aiding in diagnosis. Other diagnostic methods, which combine advanced techniques and technologies, play a supplementary role in this segment.

Imaging (Dominant) vs. Joint Fluid Analysis (Emerging)

Imaging techniques remain the dominant force in the Diagnosis segment of the Primary Osteoarthritis Market, as they facilitate clear visualization of joint structures, allowing for timely and accurate diagnoses. X-rays are particularly effective for assessing bone integrity, while MRIs provide detailed images of both hard and soft tissues, helping to detect early signs of osteoarthritis. On the other hand, joint fluid analysis, considered an emerging method, offers insights into the inflammatory processes and may guide therapeutic interventions. This segment is witnessing growing interest due to its potential to refine diagnostic accuracy and personalize treatment approaches, making it a key area for future market development.

### By Treatment: Medication (Largest) vs. Therapies (Fastest-Growing)

In the Primary Osteoarthritis Market, the distribution of treatment methods reveals that medication is the largest segment, holding a significant share due to its established role in managing symptoms. Typically comprising over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and prescription medications, this segment remains the first line of treatment for many patients. In contrast, therapies, including physical therapy, acupuncture, and other non-pharmacological approaches, have been rising in popularity, contributing to their status as the fastest-growing segment within this market.

Medication (Dominant) vs. Therapies (Emerging)

Medication continues to dominate the Primary Osteoarthritis Market, offering various options for pain relief and inflammation control. Traditional NSAIDs and newer agents play a crucial role in patient management, making this segment pivotal for treatment. Conversely, therapies are emerging as promising alternatives, emphasizing holistic approaches to symptom management. These therapies address the physical and psychological aspects of osteoarthritis, aligning with current trends in patient-centered care. As more individuals seek non-invasive and supplementary treatments to integrate with medications, the surge in demand for therapeutic interventions highlights a shift towards a more comprehensive approach to managing osteoarthritis.

### By End-user: Hospitals & Clinics (Largest) vs. Medical Institutes (Fastest-Growing)

In the Primary Osteoarthritis Market, the end-user segment is predominantly occupied by hospitals and clinics, which represent the largest portion of the market share. These facilities are crucial as they provide immediate and specialized care to osteoarthritis patients, facilitating a range of treatments from physical therapy to surgical interventions. Following closely, medical institutes have seen an increase in their share, driven by their focus on research and innovation in osteoarthritis management.

Hospitals & Clinics (Dominant) vs. Medical Institutes (Emerging)

Hospitals and clinics hold a dominant position in the Primary Osteoarthritis Market due to their comprehensive care facilities and patient volume. These institutions are equipped with the necessary technology and personnel to deliver timely diagnoses and treatments. Conversely, medical institutes are emerging as key players, prioritizing research and development related to osteoarthritis therapies. Their increasing investments in clinical trials and innovative treatment modalities contribute to their rapid growth. As they expand their capabilities, they enhance patient outcomes and satisfaction, making them an integral part of the evolving landscape of osteoarthritis care.

## Regional Market Share Analysis

### North America : Healthcare Innovation Leader

North America is the largest market for primary osteoarthritis, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of osteoarthritis, and significant investments in research and development. Regulatory support from agencies like the FDA accelerates the approval of new therapies, driving market growth. The increasing aging population and rising obesity rates further fuel demand for effective treatments. The competitive landscape in North America is robust, featuring key players such as Pfizer, Johnson & Johnson, and AbbVie. These companies are at the forefront of developing innovative therapies, including biologics and disease-modifying osteoarthritis drugs (DMOADs). The presence of leading pharmaceutical firms ensures a continuous pipeline of new products, enhancing treatment options for patients. The market is characterized by strategic collaborations and partnerships aimed at improving patient outcomes and expanding market reach.

### Europe : Emerging Market Dynamics

Europe is the second-largest market for primary osteoarthritis, accounting for approximately 30% of the global market share. The region is witnessing a rise in awareness about osteoarthritis, leading to increased diagnosis and treatment rates. Regulatory bodies like the European Medicines Agency (EMA) are actively promoting the development of new therapies, which is expected to enhance market growth. The aging population and lifestyle changes are significant drivers of demand for osteoarthritis treatments across European countries. Leading countries in Europe include Germany, France, and the UK, where healthcare systems are increasingly focusing on osteoarthritis management. The competitive landscape features major players such as Novartis, Sanofi, and GlaxoSmithKline, who are investing in research to develop innovative solutions. The market is characterized by a mix of established pharmaceutical companies and emerging biotech firms, fostering a dynamic environment for new product introductions.

### Asia-Pacific : Rapidly Growing Market

Asia-Pacific is an emerging powerhouse in the primary osteoarthritis market, holding approximately 20% of the global market share. The region is experiencing rapid growth due to rising healthcare expenditures, increasing awareness of osteoarthritis, and a growing aging population. Countries like China and India are witnessing a surge in demand for effective treatments, driven by lifestyle changes and urbanization. Regulatory frameworks are evolving to support the introduction of new therapies, further propelling market growth. The competitive landscape in Asia-Pacific is diverse, with both multinational corporations and local players vying for market share. Key players include Amgen and Merck & Co., who are expanding their presence through strategic partnerships and collaborations. The region's market is characterized by a focus on affordable treatment options, with an increasing number of generic drugs entering the market, enhancing accessibility for patients.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa represent a resource-rich frontier for the primary osteoarthritis market, holding approximately 5% of the global market share. The region is characterized by a growing awareness of osteoarthritis and an increasing focus on healthcare infrastructure development. Governments are investing in healthcare initiatives to improve access to treatments, which is expected to drive market growth. The rising prevalence of osteoarthritis due to lifestyle factors is also contributing to the demand for effective therapies. Leading countries in the region include South Africa and the UAE, where healthcare systems are evolving to address chronic conditions like osteoarthritis. The competitive landscape is gradually expanding, with both local and international players entering the market. Companies are focusing on developing affordable treatment options to cater to the diverse population, creating opportunities for growth in this untapped market.

## Competitive Benchmarking

The Primary Osteoarthritis Market is characterized by a dynamic competitive landscape, driven by an increasing prevalence of the condition and a growing demand for effective treatment options. Key players such as Pfizer (US), Johnson & Johnson (US), and AbbVie (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and biologics. These companies are actively pursuing partnerships and collaborations to enhance their product portfolios and expand their market reach. The competitive environment is shaped by these strategies, as firms seek to differentiate themselves through advanced treatment modalities and patient-centric solutions.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Novartis (CH) and Merck & Co. (US) is significant, as they continue to invest in research and development, thereby driving innovation and setting industry standards.

In August 2025, Johnson & Johnson (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel gene therapy aimed at treating osteoarthritis. This collaboration is expected to accelerate the development of innovative treatment options, potentially transforming the therapeutic landscape for patients. The strategic importance of this partnership lies in its potential to enhance J&J's product pipeline and solidify its position as a leader in the osteoarthritis market.

In September 2025, AbbVie (US) launched a new clinical trial for its investigational drug targeting pain relief in osteoarthritis patients. This initiative underscores AbbVie's commitment to addressing unmet medical needs and advancing treatment options. The trial's outcomes could significantly impact the company's market positioning, particularly if the drug demonstrates superior efficacy compared to existing therapies.

Moreover, in July 2025, Novartis (CH) expanded its global footprint by entering into a licensing agreement with a regional player in Asia, aimed at distributing its osteoarthritis treatment. This move not only enhances Novartis's market access but also reflects a broader trend of companies seeking to penetrate emerging markets. Such strategic expansions are likely to bolster competitive dynamics in the region, as local players gain access to advanced therapies.

As of October 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards innovation, technological advancements, and supply chain reliability. This transition may redefine market dynamics, as companies that prioritize these elements are likely to gain a competitive edge.

## Report Scope

| MARKET SIZE 2024 | 6.93(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 7.497(USD Billion) |
| MARKET SIZE 2035 | 16.46(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.18% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer (US), Johnson & Johnson (US), Bristol-Myers Squibb (US), Novartis (CH), AbbVie (US), Amgen (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US) |
| Segments Covered | Type |
| Key Market Opportunities | Advancements in personalized therapies and digital health solutions enhance treatment options in the Primary Osteoarthritis Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and influences treatment approaches in the Primary Osteoarthritis Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Primary Osteoarthritis Market in 2035?**
A: The projected market valuation for the Primary Osteoarthritis Market in 2035 is 16.46 USD Billion.

**Q: What was the market valuation for the Primary Osteoarthritis Market in 2024?**
A: The market valuation for the Primary Osteoarthritis Market in 2024 was 6.93 USD Billion.

**Q: What is the expected CAGR for the Primary Osteoarthritis Market from 2025 to 2035?**
A: The expected CAGR for the Primary Osteoarthritis Market during the forecast period 2025 - 2035 is 8.18%.

**Q: Which companies are considered key players in the Primary Osteoarthritis Market?**
A: Key players in the Primary Osteoarthritis Market include Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Novartis, AbbVie, Amgen, Sanofi, GlaxoSmithKline, and Merck & Co.

**Q: What segment of the Primary Osteoarthritis Market had the highest valuation in 2024?**
A: In 2024, the segment of knee osteoarthritis had the highest valuation at 2.07 USD Billion.

**Q: How much is the spinal osteoarthritis segment projected to grow by 2035?**
A: The spinal osteoarthritis segment is projected to grow from 0.69 USD Billion in 2024 to 1.63 USD Billion by 2035.

**Q: What are the projected values for the treatment segment of the Primary Osteoarthritis Market by 2035?**
A: The treatment segment is projected to grow from 2.07 USD Billion in 2024 to 4.92 USD Billion by 2035.

**Q: Which end-user segment is expected to see significant growth in the Primary Osteoarthritis Market?**
A: The hospitals & clinics end-user segment is expected to grow from 2.07 USD Billion in 2024 to 4.92 USD Billion by 2035.

**Q: What is the projected growth for the imaging diagnosis segment by 2035?**
A: The imaging diagnosis segment is projected to increase from 2.07 USD Billion in 2024 to 4.92 USD Billion by 2035.

**Q: What does the future hold for the hand osteoarthritis segment in terms of market valuation?**
A: The hand osteoarthritis segment is expected to grow from 1.04 USD Billion in 2024 to 2.45 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/primary-osteoarthritis-market-5380*